BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 32150672)

  • 1. Predicting the effect of 5-fluorouracil-based adjuvant chemotherapy on colorectal cancer recurrence: A model using gene expression profiles.
    Chen Q; Gao P; Song Y; Huang X; Xiao Q; Chen X; Lv X; Wang Z
    Cancer Med; 2020 May; 9(9):3043-3056. PubMed ID: 32150672
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transcriptional signatures for coupled predictions of stage II and III colorectal cancer metastasis and fluorouracil-based adjuvant chemotherapy benefit.
    Song K; Guo Y; Wang X; Cai H; Zheng W; Li N; Song X; Ao L; Guo Z; Zhao W
    FASEB J; 2019 Jan; 33(1):151-162. PubMed ID: 29957060
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and Construction of Combinatory Cancer Hallmark-Based Gene Signature Sets to Predict Recurrence and Chemotherapy Benefit in Stage II Colorectal Cancer.
    Gao S; Tibiche C; Zou J; Zaman N; Trifiro M; O'Connor-McCourt M; Wang E
    JAMA Oncol; 2016 Jan; 2(1):37-45. PubMed ID: 26502222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of potential pharmacogenomic markers of clinical efficacy of 5-fluorouracil in colorectal cancer.
    Nobili S; Napoli C; Landini I; Morganti M; Cianchi F; Valanzano R; Tonelli F; Cortesini C; Mazzei T; Mini E
    Int J Cancer; 2011 Apr; 128(8):1935-45. PubMed ID: 20560137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association between poorly differentiated clusters and efficacy of 5-fluorouracil-based adjuvant chemotherapy in stage III colorectal cancer.
    Tajima Y; Shimada Y; Kameyama H; Yagi R; Okamura T; Kobayashi T; Kosugi SI; Wakai T
    Jpn J Clin Oncol; 2017 Apr; 47(4):313-320. PubMed ID: 28100684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Vitro Adenosine Triphosphate-Based Chemotherapy Response Assay as a Predictor of Clinical Response to Fluorouracil-Based Adjuvant Chemotherapy in Stage II Colorectal Cancer.
    Kwon HY; Kim IK; Kang J; Sohn SK; Lee KY
    Cancer Res Treat; 2016 Jul; 48(3):970-7. PubMed ID: 26511802
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Lapucci A; Perrone G; Di Paolo A; Napoli C; Landini I; Roviello G; Calosi L; Naccarato AG; Falcone A; Bani D; Mini E; Nobili S
    Oncol Res; 2021 Mar; 28(6):631-644. PubMed ID: 33208224
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Influence of thymidylate synthase gene polymorphisms on the survival of colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Hitre E; Budai B; Adleff V; Czeglédi F; Horváth Z; Gyergyay F; Lövey J; Kovács T; Orosz Z; Láng I; Kásler M; Kralovánszky J
    Pharmacogenet Genomics; 2005 Oct; 15(10):723-30. PubMed ID: 16141798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FANCJ expression predicts the response to 5-fluorouracil-based chemotherapy in MLH1-proficient colorectal cancer.
    Nakanishi R; Kitao H; Fujinaka Y; Yamashita N; Iimori M; Tokunaga E; Yamashita N; Morita M; Kakeji Y; Maehara Y
    Ann Surg Oncol; 2012 Oct; 19(11):3627-35. PubMed ID: 22526901
    [TBL] [Abstract][Full Text] [Related]  

  • 10. LGR5 and CD133 as prognostic and predictive markers for fluoropyrimidine-based adjuvant chemotherapy in colorectal cancer.
    Stanisavljević L; Myklebust MP; Leh S; Dahl O
    Acta Oncol; 2016 Dec; 55(12):1425-1433. PubMed ID: 27435662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.
    Jover R; Zapater P; Castells A; Llor X; Andreu M; Cubiella J; Piñol V; Xicola RM; Bujanda L; Reñé JM; Clofent J; Bessa X; Morillas JD; Nicolás-Pérez D; Payá A; Alenda C;
    Gut; 2006 Jun; 55(6):848-55. PubMed ID: 16299036
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Matrix metalloproteinase 7 is a useful marker for 5-fluorouracil-based adjuvant chemotherapy in stage II and stage III colorectal cancer patients.
    Huang Y; Yu H; Lei H; Xie C; Zhong Y
    Med Oncol; 2014 Mar; 31(3):824. PubMed ID: 24469951
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of interaction between somatic APC mutations and 5-fluorouracil adjuvant chemotherapy in Taiwanese colorectal cancer subjects.
    Chen SP; Wu CC; Lin SZ; Kang JC; Su CC; Chen YL; Lin PC; Chiu SC; Pang CY; Harn HJ
    Am J Clin Oncol; 2009 Apr; 32(2):122-6. PubMed ID: 19307944
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in microRNA genes as predictors of clinical outcomes in colorectal cancer patients.
    Pardini B; Rosa F; Naccarati A; Vymetalkova V; Ye Y; Wu X; di Gaetano C; Buchler T; Novotny J; Matullo G; Vodicka P
    Carcinogenesis; 2015 Jan; 36(1):82-6. PubMed ID: 25368035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictive role of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase expression in colorectal cancer patients receiving adjuvant 5-fluorouracil.
    Ciaparrone M; Quirino M; Schinzari G; Zannoni G; Corsi DC; Vecchio FM; Cassano A; La Torre G; Barone C
    Oncology; 2006; 70(5):366-77. PubMed ID: 17179731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer.
    Ide T; Kitajima Y; Ohtaka K; Mitsuno M; Nakafusa Y; Miyazaki K
    Oncol Rep; 2008 Jun; 19(6):1571-6. PubMed ID: 18497967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer.
    Cao B; Luo L; Feng L; Ma S; Chen T; Ren Y; Zha X; Cheng S; Zhang K; Chen C
    BMC Cancer; 2017 Dec; 17(1):844. PubMed ID: 29237416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential Survival Benefits of 5-Fluorouracil-Based Adjuvant Chemotherapy for Patients With Microsatellite-Stable Stage III Colorectal Cancer According to the Tumor Budding Status: A Retrospective Analysis.
    Yamadera M; Shinto E; Kajiwara Y; Mochizuki S; Okamoto K; Hase K; Yamamoto J; Ueno H
    Dis Colon Rectum; 2019 Nov; 62(11):1316-1325. PubMed ID: 31567925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. KRT17 as a prognostic biomarker for stage II colorectal cancer.
    Ujiie D; Okayama H; Saito K; Ashizawa M; Thar Min AK; Endo E; Kase K; Yamada L; Kikuchi T; Hanayama H; Fujita S; Sakamoto W; Endo H; Saito M; Mimura K; Saze Z; Momma T; Ohki S; Kono K
    Carcinogenesis; 2020 Jul; 41(5):591-599. PubMed ID: 31754689
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictive test for chemotherapy response in resectable gastric cancer: a multi-cohort, retrospective analysis.
    Cheong JH; Yang HK; Kim H; Kim WH; Kim YW; Kook MC; Park YK; Kim HH; Lee HS; Lee KH; Gu MJ; Kim HY; Lee J; Choi SH; Hong S; Kim JW; Choi YY; Hyung WJ; Jang E; Kim H; Huh YM; Noh SH
    Lancet Oncol; 2018 May; 19(5):629-638. PubMed ID: 29567071
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.